Clinical trialNANot yet recruiting
XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer
Efficacy and Safety of XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer Patients
- Outcome
- Ongoing
- Phase
- NA
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 18 August 2025
- Expected end
- August 2030
- Enrollment
- 12 participants
- Sites
- 1
- Primary outcomes
- DFS; DFS Rate; MFS; OS
- Sponsor
- Other
- Results posted
- No
- Last update
- 11 August 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) in combination with chemotherapy as Adjuvant Therapy in pancreatic cancer patients following surgical resection.